Neurocognitive Functioning and Quality of Life in Patients with Recurrent Glioblastoma Treated with Avelumab and Axitinib

Medicine & Life Sciences

• avelumab 100%
• Axitinib 90%
• Glioblastoma 56%
• Quality of Life 36%
• Temozolomide 12%
• Self-Assessment 11%
• Neoplasms 11%
• Anxiety 11%
• Depression 10%
• Fatigue 8%
• Survival 8%
• Therapeutics 7%
• Radiotherapy 7%
• Central Nervous System Neoplasms 6%
• Investigational Therapies 6%
• Equidae 6%
• Neurobehavioral Manifestations 6%
• Drug Therapy 6%
• Age Factors 5%
• Sleep Initiation and Maintenance Disorders 5%
• Psychological Distress 5%
• Brain Neoplasms 4%
• Protein-Tyrosine Kinases 4%
• Epilepsy 4%
• Cognitive Dysfunction 4%
• Appointments and Schedules 4%
• Mental Disorders 4%
• Adrenal Cortex Hormones 4%
• Sleep 4%
• Steroids 3%
• Monoclonal Antibodies 3%
• Randomized Controlled Trials 3%
• Health Care Outcome Assessment 3%